Aclaris Therapeutics Stock Analysis
Technical stock analysis for 23 January 2019
| Shorts | n/a |
| Cash | n/a |
| Loans | n/a |
| Beta | 1.27 |
| ROA | -53.53 |
Aclaris Therapeutics fell by -1.46% in the last day from $6.15 to $6.06 and has now fallen 3 days in a row. The price has fallen in 8 of the last 10 days and is down by -21.4% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -252 719 shares and in total 289 752 shares bought and sold for approximately $1.76 million.
Close price at the end of the last trading day (Wednesday, 23rd Jan 2019) of the ACRS stock was $6.06. This is 1.46% less than the trading day before Tuesday, 22nd Jan 2019.
During day the stock fluctuated 4.81% from a day low at $6.03 to a day high of $6.32.
30 day high of the ACRS stock price was $8.19 and low was $5.95.
90 day high was $12.90 and low was $5.95.
52 week high for the Aclaris Therapeutics - $25.41 and low - $5.95.
Trend
Aclaris Therapeutics lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -45.15% during the next 3 months and, with 90% probability hold a price between $2.22 and $3.92 at the end of this period.
Signals
There are few to none technical positive signals at the moment. Aclaris Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $6.43 and $7.39. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Monday January 07, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Relative Strength Index (RSI)
The stock currently holds a RSI14 at 23 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.
Support & Resistance
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Risk
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.29 between high and low, or 4.81%. For the last week, the stock has had a daily average volatility of 6.63%.
Aclaris Therapeutics is oversold on RSI14 (23). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Overall risk:
Very Low Low Medium High Very High
Evaluation
Aclaris Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
| ACRS $6.06 $-0.09(-1.46%) |
|
ACRS is down $0.09 today, but where's it headed in 2019? |
| Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month system that more than doubles the S&P 500. Click here – the ACRS analysis is free » |
Proudly made at
in partnership with
